Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors

BACKGROUND: Anti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection are limited. We hypothesised that markers of systemic inflammation would predict adverse outcomes in multiple cancers treated with anti-PD-(L)1 agents. MATERIAL AND METHODS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Iivanainen, Sanna, Ahvonen, Jarkko, Knuuttila, Aija, Tiainen, Satu, Koivunen, Jussi Pekka
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735669/
https://ncbi.nlm.nih.gov/pubmed/31555483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000531
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados